Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas

Research output: Contribution to journalArticle

Abstract

Objective: Developing a parameter to predict bone marrow invasion by non-Hodgkin's lymphoma is an important unmet medical need for treatment decisions. This study aimed to confirm the validity of the hypothesis that bone marrow plasma vascular endothelial growth factor level might be correlated with the risk of bone marrow involvement and the prognosis of patients with diffuse large B-cell non-Hodgkin's lymphoma. Methods: Forty-nine diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone regimen were enrolled. Vascular endothelial growth factor level was measured with enzyme-linked immunosorbent assay. The validity of bone marrow plasma vascular endothelial growth factor level and bone marrow vascular endothelial growth factor level per platelet count for predicting treatment response and survival after initial rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone combined chemotherapy was assessed. Results: Bone marrow plasma vascular endothelial growth factor level per platelet count was significantly associated with old age (≥65 years), poor performance score (≥2), high International prognosis index (≥3) and bone marrow invasion. The patients with high bone marrow plasma vascular endothelial growth factor level per platelet count (≥3.01) showed a significantly lower complete response rate than the others. On Kaplan-Meier survival curves, the patients with high bone marrow plasma vascular endothelial growth factor levels (≥655 pg/ml) or high bone marrow plasma vascular endothelial growth factor level per platelet count (≥3.01) demonstrated a significantly shorter overall survival and progression-free survival than the others. In the patients without bone marrow involvement, bone marrow plasma vascular endothelial growth factor level per platelet count had a significant relationship with overall survival and progression-free survival. Multivariate analysis revealed that the patients without BM invasion showing high level of bone marrow plasma vascular endothelial growth factor per platelet count had significantly shorter progression-free survival and overall survival. Conclusions: Bone marrow plasma vascular endothelial growth factor level per platelet count might be associated with bone marrow invasion by diffuse large B-cell lymphoma and is correlated with clinical outcomes after treatment.

Original languageEnglish
Article numberhyv102
Pages (from-to)914-920
Number of pages7
JournalJapanese Journal of Clinical Oncology
Volume45
Issue number10
DOIs
Publication statusPublished - 2015 Oct 1

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Platelet Count
Vascular Endothelial Growth Factor A
Bone Marrow
Disease-Free Survival
Daunorubicin
Survival
Vincristine
Prednisolone
Non-Hodgkin's Lymphoma
Cyclophosphamide
Kaplan-Meier Estimate
B-Cell Lymphoma

Keywords

  • Bone marrow
  • Diffuse large B-cell lymphoma
  • Platelet count
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

@article{1f16836be7044bb196b6b8318aae5fc2,
title = "Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas",
abstract = "Objective: Developing a parameter to predict bone marrow invasion by non-Hodgkin's lymphoma is an important unmet medical need for treatment decisions. This study aimed to confirm the validity of the hypothesis that bone marrow plasma vascular endothelial growth factor level might be correlated with the risk of bone marrow involvement and the prognosis of patients with diffuse large B-cell non-Hodgkin's lymphoma. Methods: Forty-nine diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone regimen were enrolled. Vascular endothelial growth factor level was measured with enzyme-linked immunosorbent assay. The validity of bone marrow plasma vascular endothelial growth factor level and bone marrow vascular endothelial growth factor level per platelet count for predicting treatment response and survival after initial rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone combined chemotherapy was assessed. Results: Bone marrow plasma vascular endothelial growth factor level per platelet count was significantly associated with old age (≥65 years), poor performance score (≥2), high International prognosis index (≥3) and bone marrow invasion. The patients with high bone marrow plasma vascular endothelial growth factor level per platelet count (≥3.01) showed a significantly lower complete response rate than the others. On Kaplan-Meier survival curves, the patients with high bone marrow plasma vascular endothelial growth factor levels (≥655 pg/ml) or high bone marrow plasma vascular endothelial growth factor level per platelet count (≥3.01) demonstrated a significantly shorter overall survival and progression-free survival than the others. In the patients without bone marrow involvement, bone marrow plasma vascular endothelial growth factor level per platelet count had a significant relationship with overall survival and progression-free survival. Multivariate analysis revealed that the patients without BM invasion showing high level of bone marrow plasma vascular endothelial growth factor per platelet count had significantly shorter progression-free survival and overall survival. Conclusions: Bone marrow plasma vascular endothelial growth factor level per platelet count might be associated with bone marrow invasion by diffuse large B-cell lymphoma and is correlated with clinical outcomes after treatment.",
keywords = "Bone marrow, Diffuse large B-cell lymphoma, Platelet count, Vascular endothelial growth factor",
author = "Kim, {Jung Sun} and Gang, {Ga Won} and Lee, {Se Ryeon} and Sung, {Hwa Jung} and Young Park and Kim, {Dae Sik} and Choi, {Chul Won} and Kim, {Byung Soo}",
year = "2015",
month = "10",
day = "1",
doi = "10.1093/jjco/hyv102",
language = "English",
volume = "45",
pages = "914--920",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas

AU - Kim, Jung Sun

AU - Gang, Ga Won

AU - Lee, Se Ryeon

AU - Sung, Hwa Jung

AU - Park, Young

AU - Kim, Dae Sik

AU - Choi, Chul Won

AU - Kim, Byung Soo

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Objective: Developing a parameter to predict bone marrow invasion by non-Hodgkin's lymphoma is an important unmet medical need for treatment decisions. This study aimed to confirm the validity of the hypothesis that bone marrow plasma vascular endothelial growth factor level might be correlated with the risk of bone marrow involvement and the prognosis of patients with diffuse large B-cell non-Hodgkin's lymphoma. Methods: Forty-nine diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone regimen were enrolled. Vascular endothelial growth factor level was measured with enzyme-linked immunosorbent assay. The validity of bone marrow plasma vascular endothelial growth factor level and bone marrow vascular endothelial growth factor level per platelet count for predicting treatment response and survival after initial rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone combined chemotherapy was assessed. Results: Bone marrow plasma vascular endothelial growth factor level per platelet count was significantly associated with old age (≥65 years), poor performance score (≥2), high International prognosis index (≥3) and bone marrow invasion. The patients with high bone marrow plasma vascular endothelial growth factor level per platelet count (≥3.01) showed a significantly lower complete response rate than the others. On Kaplan-Meier survival curves, the patients with high bone marrow plasma vascular endothelial growth factor levels (≥655 pg/ml) or high bone marrow plasma vascular endothelial growth factor level per platelet count (≥3.01) demonstrated a significantly shorter overall survival and progression-free survival than the others. In the patients without bone marrow involvement, bone marrow plasma vascular endothelial growth factor level per platelet count had a significant relationship with overall survival and progression-free survival. Multivariate analysis revealed that the patients without BM invasion showing high level of bone marrow plasma vascular endothelial growth factor per platelet count had significantly shorter progression-free survival and overall survival. Conclusions: Bone marrow plasma vascular endothelial growth factor level per platelet count might be associated with bone marrow invasion by diffuse large B-cell lymphoma and is correlated with clinical outcomes after treatment.

AB - Objective: Developing a parameter to predict bone marrow invasion by non-Hodgkin's lymphoma is an important unmet medical need for treatment decisions. This study aimed to confirm the validity of the hypothesis that bone marrow plasma vascular endothelial growth factor level might be correlated with the risk of bone marrow involvement and the prognosis of patients with diffuse large B-cell non-Hodgkin's lymphoma. Methods: Forty-nine diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone regimen were enrolled. Vascular endothelial growth factor level was measured with enzyme-linked immunosorbent assay. The validity of bone marrow plasma vascular endothelial growth factor level and bone marrow vascular endothelial growth factor level per platelet count for predicting treatment response and survival after initial rituximab, cyclophosphamide, daunorubicin, vincristine and prednisolone combined chemotherapy was assessed. Results: Bone marrow plasma vascular endothelial growth factor level per platelet count was significantly associated with old age (≥65 years), poor performance score (≥2), high International prognosis index (≥3) and bone marrow invasion. The patients with high bone marrow plasma vascular endothelial growth factor level per platelet count (≥3.01) showed a significantly lower complete response rate than the others. On Kaplan-Meier survival curves, the patients with high bone marrow plasma vascular endothelial growth factor levels (≥655 pg/ml) or high bone marrow plasma vascular endothelial growth factor level per platelet count (≥3.01) demonstrated a significantly shorter overall survival and progression-free survival than the others. In the patients without bone marrow involvement, bone marrow plasma vascular endothelial growth factor level per platelet count had a significant relationship with overall survival and progression-free survival. Multivariate analysis revealed that the patients without BM invasion showing high level of bone marrow plasma vascular endothelial growth factor per platelet count had significantly shorter progression-free survival and overall survival. Conclusions: Bone marrow plasma vascular endothelial growth factor level per platelet count might be associated with bone marrow invasion by diffuse large B-cell lymphoma and is correlated with clinical outcomes after treatment.

KW - Bone marrow

KW - Diffuse large B-cell lymphoma

KW - Platelet count

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=84944406608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944406608&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyv102

DO - 10.1093/jjco/hyv102

M3 - Article

VL - 45

SP - 914

EP - 920

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

M1 - hyv102

ER -